Insulet Corporation Faces Class Action Lawsuit Over Alleged Misleading Statements
A class action lawsuit has been filed against Insulet Corporation, alleging that the company misled investors about product viability and manufacturing controls.
San Diego, CA – July 13, 2026 – Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased or acquired Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025, and May 26, 2026. The lawsuit alleges that Insulet misled investors regarding the viability of its products and its manufacturing processes.
The core of the complaint centers on allegations of defective manufacturing controls and procedures at Insulet. According to the lawsuit, these issues created a heightened risk that the company's products would violate safety regulations or pose a risk of injury. These alleged failures, the plaintiffs claim, made Insulet's public statements during the class period materially false and misleading.
Insulet disclosed a voluntary Medical Device Correction for specific lots of its Omnipod® 5 Pods in March 2026 due to a manufacturing issue. This announcement led to a 6.88% drop in the company's stock price. Subsequently, in May 2026, Insulet announced another voluntary Medical Device Correction for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod Eros Pods, citing a manufacturing issue that could result in insulin under-delivery. This news caused a further 5.07% decline in Insulet's stock price.
Robbins LLP is seeking investors who lost money in Insulet Corporation to come forward. Shareholders interested in serving as lead plaintiff have until August 31, 2026, to submit their information to the court. The firm notes that representation is on a contingency fee basis.